ASXL1 and acute myeloid leukemia: HSCT showed no significant survival benefit after landmark analysis (OS; p = 0.292).<h4>Conclusions</h4>These results demonstrate the independent prognostic value of ASXL1<sup>mut</sup>/KRAS<sup>mut</sup> co-mutation and define a novel ultra-adverse-risk subtype of acute myeloid leukemia.